Rare CKD Opportunity Target biotechnology and specialty pharmaceutical firms focusing on chronic kidney disease and metabolic acidosis, leveraging Tricida's veverimer as a niche therapy to address disease progression and related complications.

Clinical Expansion Explore partnerships with clinics and hospital systems that treat CKD patients, offering collaborative programs for veverimer to support metabolic acidosis management and potential premium pricing through outcomes-based deals.

Strategic Financing Position to investors and pharma partners highlighting Tricida's substantial funding runway and the late-stage clinical or near-commercial potential of veverimer to enable co-development or strategic licensing discussions.

Tech & Compliance Leverage the current tech stack and digital channels to drive provider education, patient engagement, and market access initiatives while ensuring data security and regulatory compliance in communications.

Risk & Communications Anticipate and address ongoing legal and fiduciary risk signals by differentiating sales strategy through transparent, risk-aware messaging and strong post-market surveillance plans to build credibility with stakeholders.